EPIVAX, INC.

Address

146 CLIFFORD STREET
PROVIDENCE, RI, -

Information

DUNS: 135531015
# of Employees: N/A

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Development of a Non-adjuvanted VLP Vaccine against Stealth H7N9 Influenza

    Amount: $300,000.00

    DESCRIPTION provided by applicant The avian origin H N influenza virus that emerged in humans in China in presents a unique challenge to vaccine development because it is poorly immunogenic ...

    SBIRPhase I2016Department of Health and Human Services
  2. EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of

    Amount: $1,474,236.00

    DESCRIPTION (provided by applicant): The goal of this Phase II project is to advance the development of novel tolerance-inducing peptides (Tregitopes) to prevent and/or treat Type 1 diabetes (T1D) by ...

    SBIRPhase II2012Department of Health and Human Services
  3. Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease Pompe disease is a lysosomal storage disorder caused by defects in the enzyme acid alpha-glucosi ...

    SBIRPhase I2012Department of Health and Human Services
  4. Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A

    Amount: $757,712.00

    DESCRIPTION (provided by applicant): The goal of this new SBIR program is to produce a combined clotting Factor VIII replacement and immunomodulatory therapy that will provide FVIII-specific tolerance ...

    SBIRPhase I2012Department of Health and Human Services
  5. T1D Tolerance Induction with Natural Treg Epitopes

    Amount: $599,999.00

    DESCRIPTION (provided by applicant): Type 1 (juvenile) diabetes is an organ-specific autoimmune disease resulting from destruction of insulinproducing pancreatic beta-cells. In non-diabetics, islet ce ...

    SBIRPhase I2008Department of Health and Human Services
  6. Optimization of a Multivalent Tuberculosis Vaccine

    Amount: $299,908.00

    DESCRIPTION (provided by applicant): This new Phase I SBIR proposal addresses the continuing worldwide need for a tuberculosis (TB) vaccine. We detail a novel multivalent strategy that aims to elicit ...

    SBIRPhase I2007Department of Health and Human Services
  7. Epitope-driven deimmunization of Factor VIII

    Amount: $263,867.00

    DESCRIPTION (provided by applicant): Hemophilia A patients are prone to develop inhibitory immune responses to the very therapy they require: Factor VIII protein replacement. Up to 30% of all hemophil ...

    SBIRPhase I2007Department of Health and Human Services
  8. A Genome-Derived, Epitope-Driven H. Pylori Vaccine

    Amount: $609,910.00

    DESCRIPTION (provided by applicant): EpiVax discovers and develops epitqpe-driven vaccines by screening microbial genomes for protective epitopes. In this application, we describe a genome-based appr ...

    SBIRPhase I2005Department of Health and Human Services
  9. Novel Smallpox Vaccine Derived from VV/VAR Immunome

    Amount: $1,027,410.00

    DESCRIPTION (provided by applicant): EpiVax specializes in the development of epitope-driven vaccines by screening whole genomes for candidate vaccine components. In this application, we propose to de ...

    SBIRPhase I2005Department of Health and Human Services
  10. A GENOME-DERIVED, EPITOPE-DRIVEN TULAREMIA VACCINE

    Amount: $831,922.00

    DESCRIPTION (provided by applicant): EpIVax specializes in the development of epitope-driven vaccines by screening whole genomes for candidate vaccine components. In this application, we describe a r ...

    SBIRPhase I2004Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government